Actualités Connect Biopharma Holdings Inc - CNTB | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:July 06, 2022...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. 333- ...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings...

Connect Biopharma to Participate at the Jefferies Healthcare Conference

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings...

Securities Registration (foreign Private Issuer) (f-3/a)

Table of Contents As filed with the Securities and Exchange Commission on May 20, 2022...

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

SAN DIEGO, CA and TAICANG, China, May 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Connect Biopharma Holdings Inc (CNTB)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

CNTB Actualités

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

Notice of Effectiveness (effect)

Securities Registration: Employee Benefit Plan (s-8)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Participate at the Jefferies Healthcare Conference

Securities Registration (foreign Private Issuer) (f-3/a)

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Connect Biopharma Holdings Inc (CNTB) Actualités

Connect Biopharma Holdings Inc (CNTB)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

CNTB Actualités

Connect Biopharma to Report First Half 2022 Financial Results on September 13

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

Notice of Effectiveness (effect)

Securities Registration: Employee Benefit Plan (s-8)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Participate at the Jefferies Healthcare Conference

Securities Registration (foreign Private Issuer) (f-3/a)

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités